Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Circle Pharma Raises $66M in Series C Financing
Circle Pharma, Inc., a South San Francisco, Calif.-based macrocycle drug discovery and development company focused on intractable cancer targets, raised $66m in Series C financing.
The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company.
The company intends to use the funds to advance its wholly owned cyclin-targeted programs towards the clinic, with potential applications in Rb-dysregulated cancers such as small cell lung cancer and cyclin E dependent malignancies, including ovarian cancer. In addition, Circle Pharma will apply its macrocycle platform to other precision oncology targets that have a clear therapeutic rationale but are considered undruggable with small molecules.
Published: Feb 01, 2021
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Constantine Kreatsoulas, PhD has joined Circle Pharma, Inc. as its Vice President of Research Informatics and Computational Chemistry.
Dr. Kreatsoulas joins Circle from GlaxoSmithKline (GSK) where he was the Head of US Molecular Design and Interim Head of Computational Toxicology. His responsibilities at GSK included leading structure-based drug design (SBDD) teams and the development of informatics tools for quantitative experimental data analytics and drug hazard identification. Previously he was a Research Fellow at Merck & Co., Inc., where he focused on SBDD, molecular modeling, machine learning, and small molecule safety assessment and a postdoctoral fellow at Bristol-Meyers Squibb focused on machine learning in predictive toxicology. Dr. Kreatsoulas was awarded a doctorate in chemistry from Princeton University, holds a master’s degree in regulatory affairs and quality assurance from Temple Un